Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Selected Grants and Awards

Publications

Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, et al. “Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer..” Gynecol Oncol 153, no. 3 (June 2019): 555–61. https://doi.org/10.1016/j.ygyno.2019.03.246.

Full Text

Deutsch, Gary B., Jeremiah L. Deneve, Mazin F. Al-Kasspooles, Valentine N. Nfonsam, Camille C. Gunderson, Angeles Alvarez Secord, Phillip Rodgers, et al. “Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)..” Am J Hosp Palliat Care, May 23, 2019. https://doi.org/10.1177/1049909119851471.

Full Text

Veade, Ashley E., Jonathan Foote, Jessie Ehrisman, Gloria Broadwater, Brittany A. Davidson, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Laura J. Havrilesky. “Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma..” World J Surg Oncol 17, no. 1 (May 10, 2019). https://doi.org/10.1186/s12957-019-1620-x.

Full Text

Lim, Stephanie L., Laura J. Havrilesky, Ashraf S. Habib, and Angeles Alvarez Secord. “Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy..” Gynecol Oncol 153, no. 2 (May 2019): 376–80. https://doi.org/10.1016/j.ygyno.2019.01.025.

Full Text

Moore, K. N., A. A. Secord, and M. A. Geller. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019).” Lancet Oncology 20, no. 5 (May 1, 2019): E242–E242.

Scholars@Duke

Moore, Kathleen N., Angeles Alvarez Secord, Melissa A. Geller, David Scott Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, et al. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial..” Lancet Oncol 20, no. 5 (May 2019): 636–48. https://doi.org/10.1016/S1470-2045(19)30029-4.

Full Text

Moore, Kathleen, John K. Chan, Angeles Alvarez Secord, Manish R. Patel, Timothy Callahan, Wei Guo, and Zhi-Yi Zhang. “Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer..” Cancer Chemother Pharmacol 83, no. 4 (April 2019): 717–26. https://doi.org/10.1007/s00280-019-03774-w.

Full Text

Puechl, Allison M., James Edwards, Anuj Suri, John Nakayama, Sarah Bean, Paola Gehrig, Erin Saks, et al. “The association between progesterone receptor expression and survival in women with adult granulosa cell tumors..” Gynecol Oncol 153, no. 1 (April 2019): 74–79. https://doi.org/10.1016/j.ygyno.2019.01.016.

Full Text

Dottino, Joseph A., Haley A. Moss, Karen H. Lu, Angeles A. Secord, and Laura J. Havrilesky. “U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis..” Obstet Gynecol 133, no. 4 (April 2019): 795–802. https://doi.org/10.1097/AOG.0000000000003171.

Full Text

Pages